Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25230408 | 0.98 | TNKS (0.45) | TNKSTNKS2AVPR1AKDM4EGLA | |
| SCHEMBL21162943 | 0.94 | TNKS (0.46) | TNKSTNKS2AVPR1AKDM4EGLA | |
| SCHEMBL4270096 | 0.90 | TNKS (0.42) | TNKSTNKS2AVPR1AKDM4EGLA | |
| SCHEMBL15781956 | 0.89 | TNKS (0.44) | TNKSTNKS2AVPR1AKDM4EGLA | |
| SCHEMBL23508720 | 0.85 | KDM1A (0.45) | TNKSTNKS2KDM4EGLASIGMAR1 | |
| SCHEMBL29479467 | 0.83 | TNKS (0.44) | TNKSTNKS2AVPR1AKDM4EKCNH2 | |
| SCHEMBL1012828 | 0.83 | TNKS (0.44) | TNKSTNKS2AVPR1AKDM4EKCNH2 | |
| SCHEMBL4268746 | 0.83 | SIGMAR1 (0.48) | TNKSTNKS2AVPR1ASIGMAR1OPRM1 | |
| SCHEMBL15007673 | 0.83 | TNKS (0.46) | TNKSTNKS2AVPR1AKCNH2HDAC1 | |
| SCHEMBL4266427 | 0.83 | TNKS (0.46) | TNKSTNKS2AVPR1AKCNH2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4379932-A | Process for preparing spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1983-04-12 | — | — | US | claimed |
| US-4379933-A | Process for preparing spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1983-04-12 | — | — | US | claimed |
| EP-3939981-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2024-04-03 | — | — | EP | disclosed |
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3939981-A1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LifeArc (GB) | 2022-01-19 | — | — | EP | disclosed |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | LIFEARC (GB) | 2021-10-05 | — | — | US | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3377501-B1 | FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS | LIFEARC (GB) | 2021-08-18 | — | — | EP | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | ASTRAZENECA UK LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| WO-1994029309-A1 | SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| EP-0615977-A1 | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO. INC. (US) | 1994-09-21 | — | — | EP | disclosed |
| US-4477667-A | Spiro[indoline-3,4'-piperidine]s and related compounds | AMERICAN HOECHST CORPORATION (US) | 1984-10-16 | — | — | US | disclosed |
| US-4408050-A | Spiro(indoline-3,4'-piperidine) and related compounds | AMERICAN HOECHST CORPORATION (US) | 1983-10-04 | — | — | US | disclosed |
| US-4379932-A | Process for preparing spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1983-04-12 | — | — | US | disclosed |
| US-4379933-A | Process for preparing spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1983-04-12 | — | — | US | disclosed |
| US-4345081-A | Spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1982-08-17 | — | — | US | disclosed |
| US-4307235-A | Spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1981-12-22 | — | — | US | disclosed |
| US-4209625-A | Spiro[indoline-3,4'-piperidine]s | AMERICAN HOECHST CORPORATION (US) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247822-A1 | Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors | MAPT, TTBK1, TTBK2 | TNKS 54/4885TNKS2 107/4885AVPR1A 4874/4885 |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | TNKS 345/4885TNKS2 325/4885AVPR1A 4523/4885 |
| US-11136338-B2 | Fused thiazolopyrimidine derivatives as MNKs inhibitors | MAPT, TTBK1, TTBK2 | TNKS 54/4885TNKS2 107/4885AVPR1A 4874/4885 |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | TNKS 345/4885TNKS2 325/4885AVPR1A 4523/4885 |
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | TNKS 2035/4885TNKS2 2205/4885AVPR1A 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.